Select Page

Our consultancy provides strategic direction and tactical execution for development of novel pharmaceuticals and medical devices

Development

Medical product development is a complex, expensive, risky venture. How does one get from early findings to an approved product? How do you get to the key milestones as rapidly and efficiently as possible?

Gary Novack, Ph.D.

Gary D. Novack, Ph.D., President of PharmaLogic Development, Inc. has decades of experience in successful product development. Together with his team of senior experts, PharmaLogic can help you execute that plan.

Expertise

In our 30+ years working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology). 

Based upon decades of successful product development experience, PharmaLogic Development, Inc., can help you develop and execute a strategic plan for your product. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, our expertise is in local therapy (ophthalmology and dermatology).

Dr. Novack states “The more I work in the development of new pharmaceuticals, the more I see that early development is a complex interaction of pharmaceutics (formulation), safety assessment (local and systemic), and clinical planning. Not only do we help plan and execute what needs to be done, but what needs to be done when.”

Many of his experiences and unique perspectives in product development may be found in the over two dozen editorials he has written as a contributing editor to The Ocular Surface.

If you don’t know where you are going, any road will get you there.
– Lewis Carroll

Compounding of Low-Concentration Atropine for Myopia Control

I call attention to this paper of mine just published in Eye & Contact Lens together with colleagues Drs. Kathryn Richdale, Erin Tomiyama and Mark Bullimore – a survey of the variability of atropine formulation, sterility and stability testing and storage requirements for compounded low dose atropine for myopia prevention.

Read More »

Dr. Novack honored by American Academy of Ophthalmology

Gary D. Novack, Ph..D. was honored by the American Academy of Ophthalmology (AAO). In the AAO’s honors for its 2022 Annual Meeting, Dr. Novack was cited by its Secretariat for his work on the Academy’s journal, Ophthalmology Glaucoma. Dr. Novack serves as both an author and reviewer for this journal.

Read More »

Gary Novack presents talk on new glaucoma drugs

Dr. Gary Novack presented an invited talk on “Why are there not more new glaucoma drugs” at the August meeting of the Glaucoma Research Society. The Glaucoma Research Society is a public interest, non-profit scientific association of outstanding glaucoma researchers that provides a forum to discuss and stimulate compelling or

Read More »